This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
A remote semaglutide-supported weight program achieved 19.1% weight loss in active subscribers at 12 months, with 78% losing 10%+ and 62% losing 15%+. However, 60% of participants became inactive.
Why it matters
While completers achieved impressive results comparable to clinical trials, the 60% dropout rate shows that engagement is the biggest challenge for remote obesity programs, even with effective medication.
The numbers in context
341 baseline participants (82.7% women, mean BMI 37.9). Active at 12 months: 39.6%. Active subscribers: -20.0 kg (-19.1%). 77.7% lost 10%+, 61.5% lost 15%+. 69.6% reported no side effects by month 12.
How the study worked
Retrospective service evaluation of a commercial remote weight program (Second Nature). Participants started Sept-Dec 2023. Paired t-tests for outcomes. Qualitative experience analysis.
Who was studied
UK adults with obesity using semaglutide in a remote digital weight management program
What this study cannot tell us
60% dropout rate limits generalizability. Weight data available for only 52.5% at 12 months. No intent-to-treat analysis. Single commercial program. UK-specific.
Read the original research
A Remotely Delivered GLP-1RA-Supported Specialist Weight Management Program in Adults Living With Obesity: Retrospective Service Evaluation.
JMIR formative research, 9, e72577
Citation
Richards, Rebecca; Whitman, Michael; Wren, Gina; Campion, Peta. (2025). A Remotely Delivered GLP-1RA-Supported Specialist Weight Management Program in Adults Living With Obesity: Retrospective Service Evaluation.. JMIR formative research, 9, e72577. https://doi.org/10.2196/72577